Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
Authors
Keywords
-
Journal
NEW ENGLAND JOURNAL OF MEDICINE
Volume 387, Issue 2, Pages 132-147
Publisher
Massachusetts Medical Society
Online
2022-06-05
DOI
10.1056/nejmoa2204925
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022
- (2022) Natalie S. Callander et al. Journal of the National Comprehensive Cancer Network
- Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma
- (2022) M. Martello et al. Blood Cancer Journal
- Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk
- (2022) Ruth M. de Tute et al. JOURNAL OF CLINICAL ONCOLOGY
- Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study
- (2022) Jing Dong et al. Blood Cancer Journal
- Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2021) M.A. Dimopoulos et al. ANNALS OF ONCOLOGY
- Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?
- (2021) Simone A. Minnie et al. Frontiers in Immunology
- Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN
- (2021) Peter M. Voorhees et al. Blood Advances
- The mutagenic impact of melphalan in multiple myeloma
- (2021) Francesco Maura et al. LEUKEMIA
- Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
- (2021) Ola Landgren et al. JAMA Oncology
- Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration
- (2021) Kenneth C. Anderson et al. CLINICAL CANCER RESEARCH
- What The Princess Bride Teaches Us About Outcomes in Multiple Myeloma
- (2021) Anita D'Souza et al. JOURNAL OF CLINICAL ONCOLOGY
- Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
- (2021) Philippe Moreau et al. LANCET ONCOLOGY
- Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial
- (2021) Laura Rosinol et al. BLOOD
- Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma
- (2021) Luciano J. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial
- (2021) Francesca Gay et al. LANCET ONCOLOGY
- A comprehensive review of the impact of obesity on plasma cell disorders
- (2021) Richa Parikh et al. LEUKEMIA
- Second malignancies in multiple myeloma; emerging patterns and future directions
- (2020) Kylee Maclachlan et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN
- (2020) Peter M Voorhees et al. BLOOD
- Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma
- (2020) Nisha S. Joseph et al. JOURNAL OF CLINICAL ONCOLOGY
- Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard and high risk myeloma
- (2020) Ibai Goicoechea et al. BLOOD
- Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
- (2020) Michele Cavo et al. Lancet Haematology
- Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
- (2020) Shaji K Kumar et al. LANCET ONCOLOGY
- Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial
- (2020) Saad Z Usmani et al. Lancet Haematology
- Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma
- (2019) Isabel G. Amsler et al. LEUKEMIA & LYMPHOMA
- With equal access, African Americans have superior survival compared to Caucasians with Multiple Myeloma: a VA study
- (2019) Nathanael R Fillmore et al. BLOOD
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
- (2019) Philippe Moreau et al. LANCET
- Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autotransplants for Lymphomas and Plasma Cell Myeloma
- (2018) Tomas Radivoyevitch et al. LEUKEMIA RESEARCH
- Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
- (2018) Aurore Perrot et al. BLOOD
- Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
- (2018) Paul G. Richardson et al. Blood Cancer Journal
- Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
- (2017) Philip L. McCarthy et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
- (2017) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma
- (2016) Idrees Mian et al. CANCER
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
- (2010) P. G. Richardson et al. BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More